Prevalence of BRCA mutations and founder effect in high-risk Hispanic families - PubMed (original) (raw)
Prevalence of BRCA mutations and founder effect in high-risk Hispanic families
Jeffrey N Weitzel et al. Cancer Epidemiol Biomarkers Prev. 2005 Jul.
Abstract
Approximately 12% of the U.S. population is Hispanic, with the majority residing in urban centers such as Los Angeles. The prevalence of BRCA mutations among high-risk Hispanic families is unknown.
Methods: One hundred and ten unrelated probands of Hispanic origin, with a personal or family history of breast and/or ovarian cancer, presented for genetic cancer risk assessment, were enrolled in an Institutional Review Board-approved registry and underwent BRCA testing. Haplotype analyses were done if BRCA mutations were observed in two or more unrelated probands.
Results: Mean age at diagnosis was 37 years (range = 23-59) for the 89 (81%) probands with invasive breast cancer. Overall, 34 (30.9%) had deleterious mutations (25 in BRCA1, 9 in BRCA2), 25 (22.7%) had one or more unclassified variants, and 51 (46.4%) had negative results. The mean pretest mutation probability using the Couch model, Myriad model, and BRCAPro was 19.6% (range = 4-77%). The combined average mutation probability was 32.8% for carriers, 15.5% for noncarriers, and 12.9% for variant carriers (P < 0.0001). The most common deleterious mutation was 185delAG (4 of 34, 11.8%). The Hispanic 185delAG carrier families share the same haplotype from D17s1320 through BRCA1, as do two reference Ashkenazi Jewish families. Haplotype analyses of additional recurrent BRCA1 mutations [IVS5+1G>A (n=2),S955X (n = 3), R1443X (n = 3), and 2552delC (n = 2)] also suggest founder effects, with four of six mutations seen almost exclusively in families with Latin American/Caribbean or Spanish ancestry.
Conclusion: This is the largest study to date of high-risk Hispanic families in the United States. Six recurrent mutations accounted for 47% (16 of 34) of the deleterious mutations in this cohort. The BRCA1185delAG mutation was prevalent (3.6%) in this clinic-based cohort of predominantly Mexican descent, and shared the Ashkenazi Jewish founder haplotype.
Similar articles
- High proportion of BRCA1/2 founder mutations in Hispanic breast/ovarian cancer families from Colombia.
Torres D, Rashid MU, Gil F, Umana A, Ramelli G, Robledo JF, Tawil M, Torregrosa L, Briceno I, Hamann U. Torres D, et al. Breast Cancer Res Treat. 2007 Jun;103(2):225-32. doi: 10.1007/s10549-006-9370-1. Epub 2006 Nov 2. Breast Cancer Res Treat. 2007. PMID: 17080309 - Founder and Recurrent Mutations in BRCA1 and BRCA2 Genes in Latin American Countries: State of the Art and Literature Review.
Ossa CA, Torres D. Ossa CA, et al. Oncologist. 2016 Jul;21(7):832-9. doi: 10.1634/theoncologist.2015-0416. Epub 2016 Jun 10. Oncologist. 2016. PMID: 27286788 Free PMC article. Review. - Prevalence and type of BRCA mutations in Hispanics undergoing genetic cancer risk assessment in the southwestern United States: a report from the Clinical Cancer Genetics Community Research Network.
Weitzel JN, Clague J, Martir-Negron A, Ogaz R, Herzog J, Ricker C, Jungbluth C, Cina C, Duncan P, Unzeitig G, Saldivar JS, Beattie M, Feldman N, Sand S, Port D, Barragan DI, John EM, Neuhausen SL, Larson GP. Weitzel JN, et al. J Clin Oncol. 2013 Jan 10;31(2):210-6. doi: 10.1200/JCO.2011.41.0027. Epub 2012 Dec 10. J Clin Oncol. 2013. PMID: 23233716 Free PMC article. - Identification of germline 185delAG BRCA1 mutations in non-Jewish Americans of Spanish ancestry from the San Luis Valley, Colorado.
Mullineaux LG, Castellano TM, Shaw J, Axell L, Wood ME, Diab S, Klein C, Sitarik M, Deffenbaugh AM, Graw SL. Mullineaux LG, et al. Cancer. 2003 Aug 1;98(3):597-602. doi: 10.1002/cncr.11533. Cancer. 2003. PMID: 12879478 Review. - Prevalence of BRCA1 and BRCA2 mutations in Ashkenazi Jewish families with breast and pancreatic cancer.
Stadler ZK, Salo-Mullen E, Patil SM, Pietanza MC, Vijai J, Saloustros E, Hansen NA, Kauff ND, Kurtz RC, Kelsen DP, Offit K, Robson ME. Stadler ZK, et al. Cancer. 2012 Jan 15;118(2):493-9. doi: 10.1002/cncr.26191. Epub 2011 May 19. Cancer. 2012. PMID: 21598239
Cited by
- Management and Clinical Outcomes of Breast Cancer in Women Diagnosed with Hereditary Cancer Syndromes in a Clinic-Based Sample from Colombia.
Sanabria-Salas MC, Pedroza-Duran A, Díaz-Casas SE, Nuñez Lemus M, Grillo-Ardila CF, Briceño-Morales X, García-Mora M, Ángel-Aristizábal J, Mariño Lozano IF, Suarez Rodríguez RA, Guzmán Abisaab LH. Sanabria-Salas MC, et al. Cancers (Basel). 2024 May 26;16(11):2020. doi: 10.3390/cancers16112020. Cancers (Basel). 2024. PMID: 38893140 Free PMC article. - Using species richness calculations to model the global profile of unsampled pathogenic variants: Examples from BRCA1 and BRCA2.
Rao ND, Shirts BH. Rao ND, et al. PLoS One. 2023 Feb 8;18(2):e0278010. doi: 10.1371/journal.pone.0278010. eCollection 2023. PLoS One. 2023. PMID: 36753473 Free PMC article. - Germline Pathogenic Variant Prevalence Among Latin American and US Hispanic Individuals Undergoing Testing for Hereditary Breast and Ovarian Cancer: A Cross-Sectional Study.
Ossa Gomez CA, Achatz MI, Hurtado M, Sanabria-Salas MC, Sullcahuaman Y, Chávarri-Guerra Y, Dutil J, Nielsen SM, Esplin ED, Michalski ST, Bristow SL, Hatchell KE, Nussbaum RL, Pineda-Alvarez DE, Ashton-Prolla P. Ossa Gomez CA, et al. JCO Glob Oncol. 2022 Jul;8:e2200104. doi: 10.1200/GO.22.00104. JCO Glob Oncol. 2022. PMID: 35867948 Free PMC article. - Clinical Benefits of Olaparib in Mexican Ovarian Cancer Patients With Founder Mutation _BRCA1_-Del ex9-12.
Gallardo-Rincón D, Montes-Servín E, Alamilla-García G, Montes-Servín E, Bahena-González A, Cetina-Pérez L, Morales Vásquez F, Cano-Blanco C, Coronel-Martínez J, González-Ibarra E, Espinosa-Romero R, María Alvarez-Gómez R, Pedroza-Torres A, Castro-Eguiluz D. Gallardo-Rincón D, et al. Front Genet. 2022 Jun 6;13:863956. doi: 10.3389/fgene.2022.863956. eCollection 2022. Front Genet. 2022. PMID: 35734436 Free PMC article. - Disparities in Cancer Genetic Testing and Variants of Uncertain Significance in the Hispanic Population of South Texas.
Soewito S, Wyatt R, Berenson E, Poullard N, Gessay S, Mette L, Marin E, Shelby K, Alvarez E, Choi BY, Aviles C, Pulido-Saldivar AM, Otto PM, Jatoi I, Ramamurthy C, Ignatius M, Kaklamani VG, Tomlinson GE. Soewito S, et al. JCO Oncol Pract. 2022 May;18(5):e805-e813. doi: 10.1200/OP.22.00090. JCO Oncol Pract. 2022. PMID: 35544645 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous